Abstract
Transplantation of potentially therapeutic cells into the subretinal space is a promising prospective therapy for the treatment of retinal degenerative diseases including age-related macular degeneration (AMD). In rodent models with photoreceptor degeneration, subretinal transplantation of cell suspensions has repeatedly been demonstrated to rescue behaviorally measured vision, maintain electrophysiological responses from the retina and the brain, and slow the degeneration of rod and cone photoreceptors for extended periods. These studies have led to the initiation of a number of FDA-approved clinical trials for application of cell-based therapy for AMD and other retinal degenerative diseases. However, translation from rodent models directly into human clinical trials skips an important intermediary preclinical step that is needed to address critical issues for intraocular cell transplantation. These include determination of the most appropriate and least problematic surgical approach, the application of treatment in an eye with similar size and structure including the presence of a macula, and a thorough understanding of the immunological considerations regarding graft survival and the consequences of grafted cell rejection. This chapter will review these and related issues and will document current efforts to address these concerns.
| Original language | English (US) |
|---|---|
| Title of host publication | Advances in Experimental Medicine and Biology |
| Publisher | Springer New York LLC |
| Pages | 641-647 |
| Number of pages | 7 |
| DOIs | |
| State | Published - Jan 1 2018 |
Publication series
| Name | Advances in Experimental Medicine and Biology |
|---|---|
| Volume | 1074 |
| ISSN (Print) | 0065-2598 |
| ISSN (Electronic) | 2214-8019 |
Fingerprint
Keywords
- Cell transplantation
- Immune rejection
- Nonhuman primate
- Retinal pigment epithelial cells
- Surgery
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Cell transplantation for retinal degeneration : Transition from rodent to nonhuman primate models. / McGill, Trevor; Wilson, David; Stoddard, Jonathan; Renner, Lauren M.; Neuringer, Martha.
Advances in Experimental Medicine and Biology. Springer New York LLC, 2018. p. 641-647 (Advances in Experimental Medicine and Biology; Vol. 1074).Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Cell transplantation for retinal degeneration
T2 - Transition from rodent to nonhuman primate models
AU - McGill, Trevor
AU - Wilson, David
AU - Stoddard, Jonathan
AU - Renner, Lauren M.
AU - Neuringer, Martha
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Transplantation of potentially therapeutic cells into the subretinal space is a promising prospective therapy for the treatment of retinal degenerative diseases including age-related macular degeneration (AMD). In rodent models with photoreceptor degeneration, subretinal transplantation of cell suspensions has repeatedly been demonstrated to rescue behaviorally measured vision, maintain electrophysiological responses from the retina and the brain, and slow the degeneration of rod and cone photoreceptors for extended periods. These studies have led to the initiation of a number of FDA-approved clinical trials for application of cell-based therapy for AMD and other retinal degenerative diseases. However, translation from rodent models directly into human clinical trials skips an important intermediary preclinical step that is needed to address critical issues for intraocular cell transplantation. These include determination of the most appropriate and least problematic surgical approach, the application of treatment in an eye with similar size and structure including the presence of a macula, and a thorough understanding of the immunological considerations regarding graft survival and the consequences of grafted cell rejection. This chapter will review these and related issues and will document current efforts to address these concerns.
AB - Transplantation of potentially therapeutic cells into the subretinal space is a promising prospective therapy for the treatment of retinal degenerative diseases including age-related macular degeneration (AMD). In rodent models with photoreceptor degeneration, subretinal transplantation of cell suspensions has repeatedly been demonstrated to rescue behaviorally measured vision, maintain electrophysiological responses from the retina and the brain, and slow the degeneration of rod and cone photoreceptors for extended periods. These studies have led to the initiation of a number of FDA-approved clinical trials for application of cell-based therapy for AMD and other retinal degenerative diseases. However, translation from rodent models directly into human clinical trials skips an important intermediary preclinical step that is needed to address critical issues for intraocular cell transplantation. These include determination of the most appropriate and least problematic surgical approach, the application of treatment in an eye with similar size and structure including the presence of a macula, and a thorough understanding of the immunological considerations regarding graft survival and the consequences of grafted cell rejection. This chapter will review these and related issues and will document current efforts to address these concerns.
KW - Cell transplantation
KW - Immune rejection
KW - Nonhuman primate
KW - Retinal pigment epithelial cells
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85046624540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046624540&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-75402-4_78
DO - 10.1007/978-3-319-75402-4_78
M3 - Chapter
C2 - 29721998
AN - SCOPUS:85046624540
T3 - Advances in Experimental Medicine and Biology
SP - 641
EP - 647
BT - Advances in Experimental Medicine and Biology
PB - Springer New York LLC
ER -